Matinas BioPharma Holdings (MTNB) Total Liabilities (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Total Liabilities data on file, last reported at $2.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $2.9 million, down 50.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 50.53% YoY), and the FY2025 annual result was $2.4 million, down 52.92% from the prior year.
• Total Liabilities improved to $2.9 million in Q1 2026 per MTNB's latest filing, from $2.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $9.6 million in Q2 2022 and troughed at $2.4 million in Q4 2025.
• A 5-year average of $5.7 million and a median of $5.6 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 39.84% in 2022, then tumbled 52.92% in 2025.
• A 5-year view of Total Liabilities shows it stood at $8.2 million in 2022, then declined by 28.4% to $5.9 million in 2023, then dropped by 13.78% to $5.1 million in 2024, then plunged by 52.92% to $2.4 million in 2025, then climbed by 19.93% to $2.9 million in 2026.
• Business Quant data shows MTNB's Total Liabilities at $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $3.2 million in Q3 2025.